

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-217)

PAVURUTAMAB

PRONUNCIATION

pa" vue rue' ta mab

THERAPEUTIC CLAIM

Treatment of multiple myeloma

CHEMICAL NAMES

1. Immunoglobulin, anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human monoclonal bra-hwzv 1 single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen ϵ -chain) (human monoclonal bra-hwzv 1 single-chain variable fragment VH2-(GGGGS)3-VL2) fusion protein with fusion protein with peptide linker (GGGG) fusion protein with immunoglobulin G1 (human γ 1-chain C-region C-terminal fragment) fusion protein with peptide linker (GGGGS)6 fusion protein with immunoglobulin G1 (human γ 1-chain C-region C-terminal fragment) (Source: CAS)
2. Immunoglobulin scFv-scFv-scFc, anti-(*Homo sapiens* Tumor necrosis factor receptor superfamily member 17 (B-cell maturation protein, CD269_antigen)) **TNR17** and anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain (T-cell surface antigen T3/Leu-4 epsilon chain, CD3e_antigen)) **CD3E**; monoclonal antibody single chain; bispecific; Variable chains (1-502); anti-**TNR17** (1-249): [*Homo sapiens* VH (IGHV1-46*01 {G49>C(44)} (85%) – (IGHD)-IGHJ4*01 (93%)] [8.8.14] (1-121) -tris(tetraglycylseryl) linker (122-136), [*Homo sapiens* V-KAPPA (IGKV1-33*01 (92%) –IGKJ1*01 {Q120>C(236)} (92%)] [6.3.9] (137-243), -seryltetraglycylseryl linker (244-249); anti-**CD3E** (250-502): [VH (*Mus musculus* IGHV10-1*02 (92%)–(IGHD)-IGHJ3*01 (87%)/*Homo sapiens* IGHV3-73*01 (87%) –(IGHD)-IGHJ5*01)] [8.10.16] (250-374) -tris(tetraglycylseryl) linker (375-389) V-LAMBDA (*Homo sapiens* IGLV7-43*01 (85%) IGLJ3*02) [9.3.9] (390-498), -(tetraglycyl) linker (499-502) Constant chains (503-986), *Homo sapiens* IGHG1*03 {CH1 del, [hinge 6-15 (503-512)], [CH2 R⁶²>C(574), N⁶⁷>G(579), V⁷²>C(584)] (503-729) -hexakis(tetraglycylseryl) linker (730-759) *Homo sapiens* IGHG1*03 {CH1 del, [hinge 6-15 (760-769)], [CH2 R⁶²>C(831), N⁶⁷>G(836), V⁷²>C(841)] (760-986)], non-glycosylated, produced in CHO cell. (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA

Sequence


QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	NHIIHWVQA	PGQCLEWMGY	50
INPYPGYHAY	NEKFQGRATM	TSDTSTSTVY	MELSSLRSED	TAVYYCARDG	100
YRDTDVLVDY	WGQGLVTVS	SGGGSGGGG	SGGGGSDIQM	TQSPSSLSAS	150
VGDRVITITCQ	ASQDISNYLN	WYQQKPGKAP	KLLIYYTSRL	HTGVPSRFSG	200
SGSGTDFTFT	ISSLEPEDIA	TYQCQQGNTL	PWTFGCCTKV	EIKSGGGGSE	250
VQLVESGGGL	VQPGGSLKLS	CAASGFTFNK	YAMNWRQAP	GKGLEWVARI	300
RSKYNNYATY	YADSVKDRFT	ISRDDSKNTA	YMQMNNLKTE	DTAVYYCVRH	350
GNFGNSYISY	WAYWGQGLV	TVSSGGGGSG	GGGSGGGGSQ	TVVVTQEPSLT	400

VSPGGT V TLT	CGSSTGAVTS	GNYPNWVQK	PGQAPRGLIG	GTKFLAPGTP	450
ARFSGSLLGG	KAALTL S GVQ	PEDEAEYYCV	LWYSNRWVFG	GGTKLTVLGG	500
GGDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	DTLMISRTP	VTCVVVDVSH	550
EDPEVKFNWY	VDGVEVHNAK	TKPCEEQYGS	TYRCVSVLTV	LHQDWLNGKE	600
YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	YTLPPSREEM	TKNQVSLTCL	650
VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL	DSDGSFFLYS	KLTVDKSRWQ	700
QGNVFS S V	HEALHNHYTQ	KSLSLSPGKG	GGSGGGGSG	GGSGGGGSG	750
GGSGGGGSD	KTHTCPPCPA	PELLGGPSVF	LFPPKPKDTL	MISRTP E VTC	800
VVVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	CEEQYGSTYR	CVSVLTVLHQ	850
DWLNGKEYKC	KVSNKALPAP	IEKTI S KAKG	QPREPQVYTL	PPSREEMTKN	900
QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTPVLDSD	GSFFLYSKLT	950
VDKSRWQQGN	VFSCSVMHEA	LHNHYTQKSL	SLSPGK		986

Disulfide bridges location

22-96	44-236	159-224	271-347	411-479	508-765	511-768
543-603	574-584	649-707	800-860	831-841	906-964	

Modifications



MOLECULAR FORMULA C₄₆₈₄H₇₁₅₄N₁₂₆₈O₁₄₆₆S₃₈

MOLECULAR WEIGHT 105.90 kDa

TRADEMARK None as yet

SPONSOR Amgen Inc.

CODE DESIGNATIONS AMG-701

CAS REGISTRY NUMBER 2250292-39-6

UNII GLR3JG8TZU

WHO NUMBER 11290

gbk